NEW YORK – Quest Diagnostics received on Tuesday Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 rRT PCR test.
The issuance allows Quest to provide the test for individuals suspected by their healthcare providers of having COVID-19.
On Saturday, the company said that between the capacity provided by its own test as well as other authorized in vitro diagnostic SARS-CoV-2 test kits, it expected to be able to perform roughly 10,000 tests a day by the end of this week and roughly 20,000 tests per day by the end of March.
Quest is running its SARS-CoV-2 test in its high-complexity laboratories in Chantilly, Virginia and Marlborough, Massachusetts and high-throughput IVD test at a number its regional laboratories. It began running the test earlier this month after the FDA allowed high-complexity labs to develop their own test for the coronavirus.